US watchdog requests additional safety trial of Astra's roxadustat Read More
LONDON BROKER RATINGS: Liberum says buy Made.com; RBC cuts ConvaTec Read More
LONDON MARKET OPEN: Hargreaves Lansdown falls on higher costs warning Read More
AstraZeneca's Forxiga gets EU approval for kidney disease treatment Read More
LONDON BRIEFING: HL pays special dividend after "extraordinary" year Read More
UK dividends calendar - next 7 days Read More
Pressure grows to recall MPs to debate UK vaccine passports proposal Read More
AstraZeneca's Saphnelo gets FDA approval in US for systemic lupus Read More
TOP NEWS: AstraZeneca Covid jab sales top USD1 billion in first half Read More
LONDON BRIEFING: Lloyds Banking to Embark on wealth management drive Read More
UK sends first of 100 million promised vaccine doses to poorer nations Read More
Hutchmed research costs deepen loss; expects US launches in 2022, 2023 Read More
IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial Read More
AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25% Read More
AstraZeneca partners with Regeneron to research obesity treatment Read More
AstraZeneca drug Ultomiris recommended in EU for rare blood disorder Read More
TOP NEWS: AstraZeneca vaccine effective after one dose, study shows Read More
UK earnings, trading statements calendar - next 7 days Read More
EXECUTIVE CHANGES: Nuformix responds to "frustration" as CEO departs Read More
AstraZeneca completes buy of rare diseases specialist Alexion Read More
